obesity drug news today glp-1 october 21 2025 Market Obesity GLP-1 Market Size to

5 Saxenda (liraglutide) is injected subcutaneously (under the skin) usually once daily, with or without meals

Therefore, it is imperative for clinicians to remain aware of emerging evidence and advancements in this dynamic therapeutic domain (See Figures 4 and 5)

Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease

Please visit Ozempic.com or Wegovy.com for a full list of important safety information for these medications

Some people may be prescribed 1.8 milligrams

As the insulinotropic effects are glucose-dependent and the counterregulatory response of glucagon to hypoglycaemia remains intact with GLP-1 infusion [19], the risk of hypoglycaemia is low